David Alan Campbell Sells 25,000 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell sold 25,000 shares of the company’s stock in a transaction on Tuesday, December 24th. The shares were sold at an average price of $56.19, for a total value of $1,404,750.00. Following the completion of the transaction, the chief executive officer now owns 217,054 shares of the company’s stock, valued at $12,196,264.26. This trade represents a 10.33 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

David Alan Campbell also recently made the following trade(s):

• On Tuesday, December 3rd, David Alan Campbell sold 15,000 shares of Janux Therapeutics stock. The stock was sold at an average price of $67.00, for a total transaction of $1,005,000.00.
• On Monday, November 25th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The stock was sold at an average price of $51.60, for a total transaction of $1,290,000.00.
• On Monday, October 28th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $53.54, for a total transaction of $1,338,500.00.

Janux Therapeutics Price Performance

NASDAQ JANX opened at $54.10 on Friday. The company’s 50 day simple moving average is $54.43 and its two-hundred day simple moving average is $47.46. Janux Therapeutics, Inc. has a 1 year low of $7.79 and a 1 year high of $71.71. The stock has a market capitalization of $2.84 billion, a PE ratio of -46.24 and a beta of 3.29.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The business had revenue of $0.44 million during the quarter, compared to analysts’ expectations of $1.50 million. The company’s revenue was down 82.6% compared to the same quarter last year. On average, research analysts anticipate that Janux Therapeutics, Inc. will post -1.35 EPS for the current year.

Institutional Trading of Janux Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Charles Schwab Investment Management Inc. increased its position in shares of Janux Therapeutics by 202.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock worth $10,639,000 after purchasing an additional 156,675 shares during the last quarter. Ally Bridge Group NY LLC purchased a new position in Janux Therapeutics in the 3rd quarter worth approximately $4,943,000. Algert Global LLC purchased a new position in Janux Therapeutics in the 3rd quarter worth approximately $1,112,000. FMR LLC increased its holdings in shares of Janux Therapeutics by 0.6% in the 3rd quarter. FMR LLC now owns 7,824,675 shares of the company’s stock worth $355,475,000 after buying an additional 47,075 shares during the last quarter. Finally, Neo Ivy Capital Management purchased a new stake in shares of Janux Therapeutics during the 3rd quarter valued at $940,000. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Wall Street Analyst Weigh In

JANX has been the topic of several research analyst reports. Leerink Partnrs upgraded Janux Therapeutics to a “strong-buy” rating in a research note on Friday, November 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $200.00 price target on shares of Janux Therapeutics in a research report on Wednesday, December 11th. BTIG Research lifted their price objective on Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. Stifel Nicolaus upped their price objective on shares of Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a report on Tuesday, December 3rd. Finally, UBS Group began coverage on shares of Janux Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $69.00 target price for the company. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Janux Therapeutics currently has a consensus rating of “Buy” and an average price target of $89.90.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.